About: Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on May 2016

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2016 (ast) наукова стаття, опублікована в травні 2016 (uk) مقالة علمية نشرت في مايو 2016 (ar) scientific article published on May 2016 (en)
publication date	wds:Q37064697-E7503E1F-2B81-4D70-B834-E778913858FF
publication date	2016-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37064697-24DE82AB-C9D8-4A1E-854C-748B7186D8EB
language of work or name	English
cites work	wds:Q37064697-146DED31-4985-4757-8A20-35C6E191CD39 wds:Q37064697-1E12BD4F-26E7-4DA2-99C6-6B5E13A7872D wds:Q37064697-2414DE86-EFB8-4127-B09B-6F5262D866AE wds:Q37064697-392A448B-B1FE-4AE7-BE42-1F75C5B88E5C wds:Q37064697-46C6BDF4-6388-4A7B-A663-4F43C45FB12D wds:Q37064697-489E399F-C622-411C-931C-9CA09E57D136 wds:Q37064697-4EB59F58-986C-49FE-8717-7A5A869807A1 wds:Q37064697-599F4B05-1828-498A-ACCE-4AFCE7E52BE6 wds:Q37064697-65A5FF39-7A1D-4410-968F-6B6E19FDD356 wds:Q37064697-8D8C63A0-D343-4506-8B64-BBB6AA2348B8 wds:Q37064697-90E72084-5929-419B-850D-90C40A962E38 wds:Q37064697-9E44BF5F-04B4-4D44-A692-A9F11852CFFE wds:Q37064697-A0043778-5E04-494E-8233-B8492C809251 wds:Q37064697-AEC4A784-EFA8-434B-8678-6F16D9451870 wds:Q37064697-C31C7BDD-B372-4C82-BEDE-AC8882032EFF wds:Q37064697-C7CDC849-A309-4DA3-ACD6-CFA1CBB3376B wds:Q37064697-CE89A35F-C9FE-4E2A-AC12-684AD60D3C0E wds:Q37064697-D6DB9009-C280-4623-B816-319DE6E765EF wds:Q37064697-F8F6BC64-66A1-42C7-ADBB-7A20D211955F
cites work	Prevalence of vitreoretinal disorders in a rural population of southern India: the Aravind Comprehensive Eye Study Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study Ranibizumab for neovascular age-related macular degeneration Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2 A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. OPTIMIZING INDIVIDUALIZED THERAPY WITH BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therap Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration.
author name string	wds:Q37064697-1EAD3A4A-B8A0-44DA-935F-6E5A92846A85 wds:Q37064697-2CF647BC-B5D9-407E-848D-0F6773FACC7C wds:Q37064697-4FB68E72-0D4B-4EC5-A6E5-62FDCE18D553
author name string	Vishal Sharma Ekta Rishi Renu Athanikar
rdfs:label	Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (en) Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (nl) Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (ast)
skos:prefLabel	Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (en) Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (nl) Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (ast)
name	Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (en) Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (nl) Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration. (ast)
author	wds:Q37064697-39C4F148-FCEF-4F0A-851E-90452702FC21 wds:Q37064697-B3ACEAFA-E43D-4C06-997B-F4BEE61A3551
author	Pukhraj Rishi Vikram Koundanya
title	wds:Q37064697-B006E8D9-D855-4C65-A102-75E4A8C6820B
title	Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration (en)
page(s)	wds:Q37064697-DC4CC9EF-0CFB-44AC-AA7D-CEF18FCA9B36
page(s)	87-92
instance of	wds:Q37064697-427FA570-D19D-4C71-BF13-D87491A5D49E
instance of	scholarly article
main subject	wds:Q37064697-F432FAF7-F62C-4380-B88B-CD9445347CCD
main subject	bevacizumab
PubMed ID	wds:Q37064697-9E3FE336-5E7A-4FF9-A24E-B06B90709FEE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27433034
PubMed ID	27433034
published in	wds:Q37064697-BDFD14BA-E8C6-45A8-9B3C-77C9938802F4
published in	Oman Journal of Ophthalmology
issue	wds:Q37064697-EC7D912F-DF3B-460A-8174-E63DA412029B
volume	wds:Q37064697-61575D3C-65F1-4A3A-A70C-A8E3DE2EDEDB
issue	2
volume	9
DOI	wds:Q37064697-63161B9E-7058-4819-A550-D61F46396A00
DOI	http://dx.doi.org/10.4103/0974-620X.184511
DOI	10.4103/0974-620X.184511
PMCID	wds:Q37064697-D2A0FF3B-CC15-4D9A-B2AD-CD11E6AFF724
PMCID	4932801

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software